Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)

被引：0
|
作者：
Straube, Andreas [1 ]
Broessner, Gregor [2 ]
Gaul, Charly [3 ]
Hamann, Xenia [4 ]
Hipp, Joachim [4 ]
Kraya, Torsten [5 ,6 ]
Schauerte, Isabel [7 ]
Neeb, Lars [8 ,9 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Headache Ctr Frankfurt, Frankfurt, Germany
[4] Teva GmbH, Ulm, Germany
[5] St Georg Hosp, Dept Neurol, Kogarah, NSW, Australia
[6] Headache Ctr Halle, Halle, Germany
[7] Inst Dr Schauerte, Munich, Germany
[8] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[9] Helios Global Hlth Berlin, Berlin, Germany
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203641
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P13-12.007
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    [J]. HEADACHE, 2023, 63 : 158 - 159
  • [2] 6-month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 260 - 260
  • [3] 6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [4] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Andreas Straube
    Gregor Broessner
    Charly Gaul
    Xenia Hamann
    Joachim Hipp
    Torsten Kraya
    Lars Neeb
    [J]. The Journal of Headache and Pain, 24
  • [5] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [6] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    [J]. HEADACHE, 2022, 62 : 156 - 157
  • [7] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
    Driessen, M. T.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S. F.
    Seminerio, M. J.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J. M.
    [J]. HEADACHE, 2021, 61 : 141 - 141
  • [8] Real-world effectiveness of switching to fremanezumab from other CGRP pathway targeting mAbs: PEARL 3rd interim analysis
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Akcicek, H.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 371 - 372
  • [9] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
    Driessen, M.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S.
    Seminerio, M.
    Carr, K.
    Sun, R.
    Totev, T.
    Yim, E.
    Ayyagari, R.
    Cohen, J.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
  • [10] Effectiveness and tolerability of monoclonal antibodies targeting CGRP pathway for migraine prevention: Real-world data from the Migraine Registry (ReMig) in the Czech Republic
    Nezadal, T.
    Dolezal, T.
    Pejrilova, D.
    Turkova, B.
    Markova, J.
    Bartkova, A.
    Klecka, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
12345